GlassScriptPhysician profile
Tarang Sharma
NPI 1912941402
$21,496.20
in general payments reported to CMS, 2019-2025
53 companies · $7,950 in 2025
The $7,950 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93.18 · 2020: $586 · 2021: $1,704 · 2022: $1,565 · 2023: $2,307 · 2024: $7,292 · 2025: $7,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,858 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,325 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,375 · Consulting Fee: $750 · Education: $166 · Travel and Lodging: $74.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,857.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,325.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,375.00 |
| Consulting Fee | $750.00 |
| Education | $165.61 |
| Travel and Lodging | $74.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $11,329.14 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,668.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,197.98 | 2020-2025 | Prolia, Tepezza, Evenity |
| Lilly USA, LLC | $919.88 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $712.26 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Xeris Pharmaceuticals, INC. | $663.35 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $494.99 | 2020-2025 | |
| Medtronic, INC. | $468.50 | 2022-2025 | Minimed 780g |
| Abbvie INC. | $396.96 | 2019-2025 | Synthroid, Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $377.23 | 2022-2024 | |
| Corcept Therapeutics | $297.00 | 2023-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.40 | 2020-2025 | Jardiance |
| Radius Health, INC. | $253.08 | 2023-2025 | Tymlos |
| Cequr Corporation | $251.14 | 2024-2025 | Cequr Simplicity |
| Insulet Corporation | $199.34 | 2021-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarang Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.